P53、CEA、CA153在三阴乳腺癌中的表达和临床意义研究

Expression and clinical significance of P53,CEA and CA153 in triple-negative breast cancer

目的:探讨P53、CEA、CA153在三阴乳腺癌中的表达特点并分析其与临床和病理之间的变化关系。方法:回顾性分析2011年3月至2015年6月上海市黄浦区中心医院乳腺外科收治的60例经术后病理证实的三阴乳腺癌患者,研究P53、CEA、CA153在其中的表达特点并分析其与临床和病理之间的变化关系。结果:60例三阴乳腺癌中,P53的表达与发病年龄、组织学级别、淋巴结转移、肿块大小、临床分期均有相关性,差异有统计学意义(P<0.05)。CEA的水平与发病年龄、组织学级别、淋巴结转移、肿块大小、临床分期均有相关性,差异有统计学意义(P<0.05)。CA153的水平与发病年龄、组织学级别、淋巴结转移、肿块大小、临床分期均有相关性,差异有统计学意义(P<0.05)。结论:P53、CEA、CA153在三阴乳腺癌中的表达与发病年龄、组织学级别、淋巴结转移、肿块大小、临床分期均有相关性,对三阴乳腺癌患者的生存有重要影响,可以作为判断三阴乳腺癌预后的重要指标。

Objective：To investigate the expression characteristics of P53, CEA and CA153 in triple negative breast cancer and analyze their relationship with clinical and pathological changes. Methods： A retrospective analysis was performed on 60 patients with breast cancer who had pathologically confirmed triple-negative breast cancer during March 2011 to June 2015 at the Breast Surgery Center of Central Hospital of Huangpu District. The expression characteristics of P53, CEA, and CA153 were studied and analyzed on their relationship with clinical and pathological changes. Results： In the 60 cases of triple-negative breast cancer, the expression of P53 was correlated with the age of onset, histological grade, lymph node metastasis, tumor size, clinical stage, and the difference was statistically significant （ P 〈 0.05）. CEA levels were related to the age of onset, histological grade, lymph node metastasis, tumor size, and clinical stage. The difference was statistically significant （ P 〈 0.05）. The level of CA153 was related to the age of onset, histological grade, lymph node metastasis, tumor size, and clinical stage, and the difference was statistically significant （ P 〈 0.05）. Conclusion： The expression of P53, CEA, and CA153 in the triple-negative breast cancer is related to the age of onset, histological grade, lymph node metastasis, tumor size, clinical stage, and has important influence on the survival of patients with triple-negative breast cancer. It can be used to determine the prognosis of triple-negative breast cancer.